Literature DB >> 12930383

Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma.

Cyrus V Hedvat1, Raymond L Comenzo, Julie Teruya-Feldstein, Adam B Olshen, Scott A Ely, Keren Osman, Yana Zhang, Nagesh Kalakonda, Stephen D Nimer.   

Abstract

Malignant plasma cells generally grow within the bone marrow microenvironment; however, they can also grow at extramedullary sites. To identify the tumour-specific alterations required for extramedullary growth, we analysed the expression profiles of a series of plasma cell neoplasms including primary multiple myeloma (MM), plasma cell leukaemia (PCL) and extramedullary plasmacytoma (EPC). Hierarchical clustering analysis segregated the EPCs from the remaining samples, and revealed an expression pattern associated with angiogenesis in the EPCs, involving higher expression of the genes TIE2, NOTCH3, CD31 and endoglin. Direct comparison of EPC samples with the MM samples identified 156 genes significantly upregulated and 85 genes significantly downregulated (P < 0.005, t-test) in the EPCs, including several genes involved in angiogenesis and adhesion that were upregulated (including angiopoietin 1, SPARC, Notch3 and fibronectin 1). Immunohistochemical staining demonstrated CD31 and endoglin protein expression in the EPC tumour cells, which are both angiogenesis related and could confer malignant plasma cells with the ability to grow outside the normal bone marrow environment. Defining how malignant plasma cell growth is regulated in the bone marrow versus at extramedullary sites will help to delineate the mechanisms underlying the dependence of tumour cell growth on angiogenesis and cell adhesion.

Entities:  

Mesh:

Year:  2003        PMID: 12930383     DOI: 10.1046/j.1365-2141.2003.04481.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  19 in total

1.  Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.

Authors:  Diana Cirstea; Teru Hideshima; Scott Rodig; Loredana Santo; Samantha Pozzi; Sonia Vallet; Hiroshi Ikeda; Giulia Perrone; Gullu Gorgun; Kishan Patel; Neil Desai; Peter Sportelli; Shweta Kapoor; Shireen Vali; Siddhartha Mukherjee; Nikhil C Munshi; Kenneth C Anderson; Noopur Raje
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

Review 2.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

3.  A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.

Authors:  Lee S Rosen; Herbert I Hurwitz; Michael K Wong; Jonathan Goldman; David S Mendelson; William D Figg; Shawn Spencer; Bonne J Adams; Delia Alvarez; Ben K Seon; Charles P Theuer; Bryan R Leigh; Michael S Gordon
Journal:  Clin Cancer Res       Date:  2012-07-05       Impact factor: 12.531

4.  Large Plasmacytoma Occupying the Upper Limb in a Myeloma Patient.

Authors:  Junichiro Takano; Kensuke Ohikata; Daisuke Nagase; Toru Igari; Kazuhiko Natori; Shotaro Hagiwara
Journal:  Rare Tumors       Date:  2017-03-30

5.  Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.

Authors:  Ping Zhou; Julie Teruya-Feldstein; Ping Lu; Martin Fleisher; Adam Olshen; Raymond L Comenzo
Journal:  Blood       Date:  2007-11-02       Impact factor: 22.113

Review 6.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

7.  Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.

Authors:  Maria G Ioannou; Efstathios Stathakis; Andreas C Lazaris; Thomas Papathomas; Evangelos Tsiambas; George K Koukoulis
Journal:  Pathol Oncol Res       Date:  2008-06-14       Impact factor: 3.201

8.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

9.  Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma.

Authors:  Juan Xu; Nanhui Yu; Pan Zhao; Fangfang Wang; Jingcao Huang; Yushan Cui; Hong Ding; Yan Yang; Yuhan Gao; Ling Pan; Hong Chang; Yu Wu; Bing Xiang; Yuping Gong; Xiao Shuai; Li Hou; Liping Xie; Ting Niu; Ting Liu; Li Zhang; Weiping Liu; Wenyan Zhang; Ying Qu; Wei Lin; Yimin Zhu; Sha Zhao; Yuhuan Zheng
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

10.  SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.

Authors:  Cesarina Giallongo; Piera La Cava; Daniele Tibullo; Ignazio Barbagallo; Nunziatina Parrinello; Alessandra Cupri; Fabio Stagno; Carla Consoli; Annalisa Chiarenza; Giuseppe A Palumbo; Francesco Di Raimondo
Journal:  BMC Cancer       Date:  2013-02-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.